---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Launch-HTN"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Launch-HTN. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 98 evidence topics quoted from 20 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/launch-htn"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Launch-HTN

<a id="heading-3.1.1"></a>

## 3.1.1 Launch-HTN

<a id="heading-3.1.1.1"></a>

### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov brief summary

> “This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resistant hypertension taking between 2 and 5 anti-hypertensive (AHT) medications.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.1-2"></a>

#### Main objective in the EU Clinical Trials Information System record

> “To assess the effect of Lorundrostat when added to prescribed AHT on SBP in subjects with hypertension”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.1-3"></a>

#### Objective stated in the publication

> “To evaluate the efficacy and safety of lorundrostat for lowering blood pressure (BP) when added to a prescribed regimen of 2 to 5 antihypertensive medications in adults with uncontrolled hypertension and treatment-resistant hypertension.”
> “The phase 3 Launch-HTN randomized clinical trial evaluated the efficacy, tolerability, and safety of lorundrostat in participants with uncontrolled hypertension, including those with apparent treatment-resistant hypertension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.2"></a>

### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-11-22”
> “Primary Completion (Actual) 2024-12-10”
> “Study Completion (Actual) 2025-01-24”
> “First Posted 2023-12-01”
> “Last Update Posted 2026-05-01”
> “No longer looking for participants”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-2"></a>

#### Number of locations in the ClinicalTrials.gov record

> “This study has 184 locations”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-3"></a>

#### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Alabama Locations”; “Arizona Locations”; “California Locations”; “Connecticut Locations”; “Florida Locations”; “Georgia Locations”; “Idaho Locations”; “Illinois Locations”; “Indiana Locations”; “Kentucky Locations”; “Louisiana Locations”; “Massachusetts Locations”; “Mississippi Locations”; “Missouri Locations”; “Nebraska Locations”; “Nevada Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Oklahoma Locations”; “Pennsylvania Locations”; “Tennessee Locations”; “Texas Locations”; “Utah Locations”; “Virginia Locations” |
| Australia | “Heidelberg Heights, Australia”; “St Albans, Australia”; “Castle Hill, New South Wales, Australia”; “Gosford, New South Wales, Australia”; “Waratah, New South Wales, Australia”; “Sippy Downs, Queensland, Australia”; “Southport, Queensland, Australia”; “Taringa, Queensland, Australia”; “Adelaide, South Australia, Australia”; “Hobart, Tasmania, Australia”; “Perth, Western Australia, Australia” |
| Bulgaria | “Gabrovo, Bulgaria”; “Pleven, Bulgaria”; “Sofia, Bulgaria”; “Stara Zagora, Bulgaria”; “Veliko Tarnovo, Bulgaria” |
| Canada | “Edmonton, Alberta, Canada”; “East York, Ontario, Canada”; “Montreal, Quebec, Canada” |
| France | “Annecy, France”; “Bordeaux, France”; “Nîmes, France”; “Saint-Priest-en-Jarez, France”; “Strasbourg, France” |
| Germany | “Berlin, Germany”; “Deggingen, Germany”; “Karlsruhe, Germany”; “Leipzig, Germany”; “Wiesbaden, Germany”; “Hanover, Lower Saxony, Germany”; “Mainz, Rhineland-Palatinate, Germany”; “Dresden, Saxony, Germany”; “Leipzig, Saxony, Germany” |
| Italy | “Ancona, Italy”; “Bologna, Italy”; “Brescia, Italy”; “Ferrara, Italy”; “Genova, Italy”; “L’Aquila, Italy”; “Messina, Italy”; “Milan, Italy”; “Modena, Italy”; “Naples, Italy”; “Pavia, Italy”; “Pisa, Italy”; “Rome, Italy”; “Rozzano, Milan, Italy”; “Roma, Rome, Italy” |
| Netherlands | “Utrecht, Netherlands”; “Nijmegen, Gelderland, Netherlands”; “Amsterdam, North Holland, Netherlands”; “Dordrecht, South Holland, Netherlands” |
| Poland | “Katowice, Poland”; “Lodz, Poland”; “Olsztyn, Poland”; “Krakow, Lesser Poland Voivodeship, Poland”; “Lubin, Polska, Poland”; “Skierniewice, Polska, Poland”; “Warsaw, Polska, Poland”; “Olsztyn, Warmian-Masurian Voivodeship, Poland” |
| Puerto Rico | “San Juan, Puerto Rico” |
| Romania | “Brasov, Romania”; “Bucharest, Romania”; “Cluj-Napoca, Romania”; “Craiova, Romania”; “Oradea, Romania”; “Timișoara, Romania”; “Târgu Mureş, Mureș County, Romania”; “Timișoara, Timiș County, Romania” |
| Spain | “Badajoz, Spain”; “Barcelona, Spain”; “Córdoba, Spain”; “Granada, Spain”; “Madrid, Spain”; “Santiago de Compostela, Spain”; “Valencia, Spain” |
| United Kingdom | “Aberdeen, United Kingdom”; “Birmingham, United Kingdom”; “Canterbury, United Kingdom”; “Carshalton, United Kingdom”; “Chippenham, United Kingdom”; “Glasgow, United Kingdom”; “Newquay, United Kingdom”; “Sheffield, United Kingdom”; “Stockton-on-Tees, United Kingdom”; “Fowey, Great Britain, United Kingdom”; “London, Great Britain, United Kingdom”; “Plymouth, Great Britain, United Kingdom”; “Torpoint, Great Britain, United Kingdom”; “Canterbury, Kent, United Kingdom” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.2-4"></a>

#### Enrollment period, sites, and countries reported in the publication

> “In this phase 3, randomized clinical trial, adults with uncontrolled hypertension, including those with treatment-resistant hypertension, were enrolled between November 2023 and September 2024 at 159 clinic sites across 13 countries. The last date of follow-up was January 24, 2025.”
> “The current double-blind, placebo-controlled randomized clinical trial screened participants at 159 sites across 13 countries. The participants were recruited by investigators from primary and secondary care clinics.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.2-5"></a>

#### EU member states, trial start, and end of trial in the EU Clinical Trials Information System record

> “Locations Germany, Romania, Italy, France, Netherlands, Spain, Poland, Bulgaria”
> “Start of trial 17/04/2024”
> “End of trial 09/01/2025”
> “Global end of trial 24/01/2025”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.2-6"></a>

#### Trial and recruitment dates by EU member state

| Member state | Status | Decision date | Trial start date | Trial end | Recruitment start | Recruitment end |
| --- | --- | --- | --- | --- | --- | --- |
| Spain | “Ended” | “08/04/2024” | “23/04/2024” | “03/01/2025” | “29/05/2024” | “18/10/2024” |
| Germany | “Ended” | “10/04/2024” | “18/04/2024” | “09/01/2025” | “28/05/2024” | “18/10/2024” |
| France | “Ended” | “10/04/2024” | “31/05/2024” | “02/01/2025” | “05/09/2024” | “18/10/2024” |
| Italy | “Ended” | “10/04/2024” | “07/05/2024” | “16/01/2025” | “04/06/2024” | “18/10/2024” |
| Netherlands | “Ended” | “11/04/2024” | “22/05/2024” | “06/01/2025” | “26/08/2024” | “18/10/2024” |
| Poland | “Ended” | “12/04/2024” | “08/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Bulgaria | “Ended” | “15/04/2024” | “17/04/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |
| Romania | “Ended” | “15/04/2024” | “27/05/2024” | “09/01/2025” | “06/06/2024” | “18/10/2024” |

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.2-7"></a>

#### Presentation and publication dates stated by the company

> “Results from Launch-HTN were presented in a late-breaking session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025) on Saturday, May 24, 2025, at 10:00am CEST.”

Source: [Mineralys Therapeutics press release, ESH 2025 Launch-HTN presentation (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/72/mineralys-therapeutics-announces-late-breaking-presentation)

<a id="heading-3.1.1.3"></a>

### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

#### Official title in the ClinicalTrials.gov record

> “A Randomized, Double-Blind, Placebo Controlled, Parallel Arm, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-2"></a>

#### Design details in the ClinicalTrials.gov record

> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”
> “Masking : Double”
> “Other Study ID Numbers MLS-101-301”
> “Phase Phase 3”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-3"></a>

#### Study periods in the ClinicalTrials.gov detailed description

> “The study consists of a 2-week screening period with a 2-week single-blind run-in period followed by a 12-week randomized, double-blind, placebo-controlled, parallel arm period. Following the randomized period subjects will be offered an opportunity to participate in an open-label extension (OLE) study.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.3-4"></a>

#### Trial phase in the EU Clinical Trials Information System record

> “Trial Phase Therapeutic confirmatory (Phase III)”
> “Medical condition(s) Uncontrolled and Resistant Hypertension”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.3-5"></a>

#### Trial phases, randomization, and stratification in the publication

> “The trial was composed of 3 phases: screening, a 2-week single-blind placebo run-in, and a 12-week randomized, double-blind treatment phase (eFigure 1 in Supplement 1). Upon completion, participants had the option to enroll in an open-label extension trial of lorundrostat or participate in a 2-week safety follow-up. Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”
> “Random permuted block sizes of 4 and 8 were used for randomization, which was stratified by geography (Australia, Canada, Europe, and the US). The randomization sequence was implemented using the Rave RTSM (a randomization and trial supply management system manufactured by Medidata).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-6"></a>

#### Blinding and oversight

> “The placebo tablets were identical in color, shape, and packaging to the tablets containing lorundrostat. Participants took 2 tablets at each dosing to ensure blinding of dose escalation after week 6. The treatment assignment was masked to participants, investigators, individuals assessing the outcomes, and individuals analyzing the data until the final database lock.”
> “An independent, unblinded data and safety monitoring committee assessed the study.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-7"></a>

#### Blood pressure measurement protocol

> “Unattended, automated office BP was assessed at screening, at randomization (baseline), at weeks 2, 4, 6, 8, and 12 during the double-blind treatment phase, and at an optional safety follow-up visit.”
> “Each site was provided with an identical automated oscillometric BP device (MicroLife WatchBP Office AFIB), training, and an instruction manual for collecting BP measurements. All BP was measured with an appropriately sized cuff on the same arm of the participant throughout the trial at approximately the same time, preferably in the morning. After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.”
> “A standing measurement followed the seated measurements to monitor for orthostatic hypotension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.3-8"></a>

#### Design described by the company: background medications continued

> “Launch-HTN reflects the real-world setting for clinicians by utilizing automated office blood pressure (AOBP) measurement and allowing participants to stay on their existing medications.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.1.4"></a>

### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

#### Inclusion criteria in the ClinicalTrials.gov record

> “At least 18 years of age at the time of signing the informed consent form (ICF)”
> “At Screening and Randomization: AOBP SBP of ≥135 and ≤180 mmHg plus AOBP DBP of ≥65 and ≤110 mmHg, or AOBP DBP of ≥90 and ≤110 mmHg”
> “Taking between 2 and 5 AHT medications”
> “History of hypertension lasting at least 6 months prior to Screening”
> “Body mass index (BMI) of ≥18 kg/m2 at Screening”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-2"></a>

#### Exclusion criteria in the ClinicalTrials.gov record

> “Women who are pregnant, plan to become pregnant, or are breastfeeding”
> “Participation in a study involving any investigational device or small-molecule drug within 4 weeks or 6 months for biologic (antibody) drugs prior to the Screening Visit”
> “eGFR <45 mL/min/1.73m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula”
> “Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization”
> “Serum sodium <135 mmol/L (corrected for hyperglycemia) at Screening.”
> “History of heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months prior to the Screening Visit.”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-3"></a>

#### Ages and sexes eligible in the ClinicalTrials.gov record

> “Ages Eligible for Study 18 Years and older”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.4-4"></a>

#### Age range in the EU Clinical Trials Information System record

> “Age range 65+ years, 18-64 years”

Source: [EU Clinical Trials Information System 2023-506425-12-00](https://euclinicaltrials.eu/ctis-public/view/2023-506425-12-00)

<a id="topic-3.1.1.4-5"></a>

#### Trial population and prohibited medications in the publication

> “Males or females aged 18 years or older with an unattended automated office systolic BP of 135 to 180 mm Hg and diastolic BP of 65 to 110 mm Hg or an isolated automated office diastolic BP of 90 to 110 mm Hg while taking stable doses of 2 to 5 prescribed antihypertensive medications (including a thiazide or thiazide-like diuretic) were eligible for inclusion.”
> “The key exclusion criteria were an estimated glomerular filtration rate (eGFR) of less than 45 mL/min/1.73 m2, a serum potassium level of greater than 5.0 mmol/L at screening or greater than 4.8 mmol/L at randomization, and a serum sodium level of less than 135 mmol/L at screening. The use of epithelial sodium channel inhibitors, MRAs, and potassium-sparing diuretics was prohibited 4 weeks prior to screening to trial completion.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.4-6"></a>

#### Additional inclusion criteria in the supplementary eMethods

> “Taking between 2 and 5 prescribed antihypertensive medications for 1 month prior Screening, include thiazide or thiazide-like diuretic which may be initiated prior/at Run-in and must remain stable until Randomization”
> “Serum cortisol (morning measurement, blood draw as close to 8 a.m. as possible but before 10 a.m.) between 3 and 22 ug/dL, inclusive, at Screening”
> “Arm circumference <52 centimeters at Screening”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.4-7"></a>

#### Additional exclusion criteria in the supplementary eMethods

> “History of clinically significant hyponatremia (sodium <130 mmol/L) or chronic and/or recurrent mild hyponatremia (sodium <135 mmol/L) within 1 year prior to Screening”
> “History of adrenal insufficiency or an abnormal ACTH stimulation test within 1 year prior to Screening”
> “Current, known or presumed white coat hypertension/significant white coat effect (>20 mmHg elevation in clinic BP compared with historical home BP monitoring assessments)”
> “Current, known or presumed orthostatic hypotension”
> “Secondary cause of hypertension with the exception of sleep apnea or primary aldosteronism with subject able to discontinue use of MRA.”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1C) >9% (>74.9 mmol/mol) at Screening”
> “Treatment with MRAs and/or ENaC inhibitors within 1 month of the Screening Visit”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="heading-3.1.1.5"></a>

### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

#### Arms and interventions in the ClinicalTrials.gov record

| Arm | Intervention |
| --- | --- |
| “Placebo Comparator: Placebo” | “Placebo once daily (QD) for 12 weeks” |
| “Experimental: Dose 1” | “50 mg lorundrostat Dose 1 once daily (QD) for 12 weeks” |
| “Experimental: Dose 2” | “50 mg lorundrostat Dose 1 once daily (QD) for 6 weeks then 100 mg lorundrostat Dose 2 once daily (QD) for 6 weeks for subjects who meet prespecified criteria” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.5-2"></a>

#### Randomization ratio and criteria for escalation to 100 mg at week 6

> “Upon confirmation of eligibility for randomization after the placebo run-in phase, participants were randomly assigned in a 1:2:1 ratio to receive 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks (n = 270) if they met prespecified criteria at week 6 (the prespecified criteria were office systolic BP ≥130 mm Hg, serum potassium level ≤4.8 mmol/L, serum sodium level ≥135 mmol/L, eGFR >45 mL/min/1.73 m2, and <25% reduction in eGFR from baseline), 50 mg of lorundrostat once daily for 12 weeks (n = 541), or placebo once daily for 12 weeks (n = 272).”
> “The participants in the lorundrostat group who did not meet all of the prespecified criteria at week 6 continued to receive the 50-mg dose for the remaining 6 weeks of double-blind treatment.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.5-3"></a>

#### Administration, dose modification, and adherence reminders

> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning. Participants were reminded about taking their trial medication using a smartphone application (AiCure).”
> “The trial medication dose could be reduced, temporarily withheld, or permanently discontinued for safety concerns at the discretion of the investigators.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.5-4"></a>

#### Background antihypertensive therapy

> “Participants continued taking their prescribed antihypertensive medications for the duration of the trial.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.6"></a>

### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

#### 3.1.1.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.1.6.1-1"></a>

##### Registered primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Change from baseline in automated office BP (AOBP) SBP at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Proportion of subjects with AOBP SBP <130 mmHg at Week 6 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 12 in subjects randomized to lorundrostat 50 mg QD with escalation to lorundrostat 100 mg QD compared to subjects randomized to placebo” | “Week 12” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 2 prescribed AHT medications” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 in subjects with uncontrolled hypertension on 3 or more prescribed AHT medications” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 6 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo” | “Week 6” |
| Secondary | “Change from baseline in AOBP SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at week 6 (within-subjects analysis)” | “Week 12” |

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.6.1-2"></a>

##### Primary outcome and key secondary outcomes in the publication

> “The primary efficacy outcome was the change in office systolic BP at week 6 for participants randomized to 50 mg of lorundrostat vs placebo. The key secondary outcomes controlled for multiplicity and included the proportion of participants with an office systolic BP of less than 130 mm Hg at week 6; change in office systolic BP at week 6 in participants taking 2 prescribed antihypertensive medications or taking 3 or more prescribed antihypertensive medications; change in office systolic BP from baseline by continuous body mass index (BMI; calculated as weight in kilograms divided by height in meters squared); change in office systolic BP at week 12; and change in office systolic BP from baseline at week 12 in participants who met prespecified criteria and were escalated from 50 mg to 100 mg of lorundrostat after week 6 (eTable 1 in Supplement 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-3"></a>

##### Primary endpoint at week 6 pooled across both lorundrostat groups

> “Efficacy evaluations at week 6 included participants in both lorundrostat groups because both groups were randomized to receive 50 mg of lorundrostat for the first 6 weeks.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-4"></a>

##### Choice of unattended automated office measurement stated by the investigators

> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.”
> “The current trial aimed to minimize the variable nature of office BP measurement by (1) obtaining measurements prior to the intake of morning medications, (2) using unattended BP measurements to limit the white-coat effect, and (3) using the mean of repeated BP measurements to reduce intraindividual variability.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-5"></a>

##### Automated office blood pressure in the American Heart Association scientific statement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”
> “Unattended AOBP has been associated with a lower prevalence of white-coat effect compared with office BP measured through auscultation and reduces the possibility of human error in BP measurement.”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.1.6.1-6"></a>

##### Difference between unattended and attended automated office measurements

> “The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.”
> “Standardized unattended AOBP measurements result in slightly lower readings than attended AOBP.”

Source: [Deragon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826897/)

<a id="topic-3.1.1.6.1-7"></a>

##### Blood pressure as the basis of benefit in FDA labeling guidance

> “However, blood pressure control is well established as beneficial in preventing serious cardiovascular events, and inadequate treatment of hypertension is acknowledged as a significant public health problem.”
> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “This observation has led us to conclude that the general, qualitative claim of cardiovascular outcome benefits pertains to all classes of antihypertensive drugs.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.1.6.1-8"></a>

##### Blood pressure in the FDA table of surrogate endpoints

| Disease or use | Patient population | Surrogate endpoint | Type of approval appropriate for |
| --- | --- | --- | --- |
| “Hypertension” | “Patients with hypertension” | “Blood pressure” | “Traditional” |

Source: [FDA Table of Surrogate Endpoints (2026)](https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure)

<a id="topic-3.1.1.6.1-9"></a>

##### Studies on a background of multiple antihypertensive drugs in FDA draft guidance

> “Drugs that lower blood pressure have been shown to reduce these risks”
> “Although FDA will not label a drug with a specific claim for resistant”
> “FDA does believe that drugs could be shown to be effective in treating”
> “Demonstrate superiority to placebo in reducing blood pressure in hypertensive patients on”
> “appropriate doses of three or more antihypertensive drugs with different mechanisms of”

Source: [FDA draft guidance, studies on a background of multiple antihypertensive drugs (2018)](https://www.fda.gov/media/114731/download)

<a id="topic-3.1.1.6.1-10"></a>

##### Cardiovascular risk reduction per 5 mm Hg lower systolic blood pressure

> “In this large-scale analysis of randomised trials, a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease, and even at normal or high–normal blood pressure values.”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.1.6.1-11"></a>

##### Key secondary endpoint: office systolic blood pressure below 130 mm Hg

> “The overarching blood pressure treatment goal is <130/80 mm Hg for all adults, with additional considerations for those who require institutional care, have a limited predicted lifespan, or are pregnant.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.6.1-12"></a>

##### Key secondary endpoint: participants taking 3 or more antihypertensive medications

> “Resistant hypertension is defined as BP above goal despite treatment with 3 antihypertensive medications with complementary mechanisms of action, including a diuretic at maximally tolerated doses or BP at goal but requiring ≥4 medications”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.6.1-13"></a>

##### Key secondary endpoint: obesity and aldosterone dysregulation

> “There is increasing awareness that primary aldosteronism and the secondary causes of increased aldosterone production, including obesity and aldosterone breakthrough, contribute significantly to elevated BP and a lack of BP control among patients with hypertension.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-14"></a>

##### Multiplicity hierarchy of the primary and secondary hypotheses

> “A graphical testing approach was used to control multiplicity for the secondary efficacy outcomes (eFigure 2 in Supplement 1). The CIs for the secondary outcomes were adjusted for multiplicity.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.6.1-15"></a>

##### Prespecified adverse events of special interest

> “Safety was assessed as the proportion of participants having received at least 1 dose of trial medication experiencing any treatment-emergent adverse events. Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="heading-3.1.1.7"></a>

### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

#### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

##### Sample size calculation and power

> “The sample size of 1000 participants randomized to 1 of 3 treatment groups in a 1:2:1 ratio had 95% power to detect a difference of 3.7 mm Hg in office systolic BP between lorundrostat (n = 750) and placebo (n = 250) at a 1-sided α level of .025, assuming a common SD of 14 mm Hg for change in office systolic BP. This sample size allowed robust safety monitoring.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-2"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 1083”

Source: [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693)

<a id="topic-3.1.1.7.1-3"></a>

##### Participants randomized and dosed by group

> “Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-4"></a>

##### Participants in the primary analysis

> “The data for lorundrostat were pooled (n = 808) and included the 538 participants from the 50-mg only group plus the 270 participants in the 50-mg dose group with the 100-mg escalation option.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.1-5"></a>

##### Participants in the responder analysis

> “A total of 790 participants in the lorundrostat 50 mg (N=524) or placebo (N=266) groups were included in the analysis”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.7.1-6"></a>

##### Participants in the chronic kidney disease analysis

> “This analysis included 808 participants with uHTN concurrently receiving >2 BP lowering medications who received either once daily LOR 50mg (N=538) or placebo (PBO) (N=270) in the Launch-HTN trial.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

> “The analysis evaluated the efficacy and safety of once-daily lorundrostat 50 mg by CKD status among 800 participants with uncontrolled or resistant hypertension enrolled in the randomized, double-blind, placebo-controlled Phase 3 Launch-HTN trial.”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.7.2"></a>

#### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

##### Intention-to-treat and safety populations

> “Included participants who received at least 1 dose of trial drug according to treatment assignment at randomization.”
> “Included participants who received at least 1 dose of trial drug according to the actual treatment they received.”
> “Participant Demographics and Characteristics at Randomization (Baseline) in the Intention-to-Treat Population.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.2-2"></a>

##### Primary estimand and analysis model

> “The primary estimand followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation. The primary outcome was analyzed on 1000 multiple imputed data using analysis of covariance with categorical factors for treatment, geographic region or country (randomization stratification factor), and treatment interaction with geographic region or country and using baseline office systolic BP as a covariate. Canada and the US were merged into 1 geographic stratum because only 3 participants were randomized in Canada.”
> “The secondary outcomes were analyzed on multiple imputed data using the analysis methods described in eTable 2 in Supplement 1.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.7.2-3"></a>

##### Intercurrent events and handling of missing data

> “Intercurrent events (IC) leading to the discontinuation of the study treatment were identified by an independent committee. Adjudications were performed prior to the database lock and unblinding.”
> “Missing data in participants with ICE due to AE were considered missing not at random (MNAR) and were multiply imputed using the Treatment Policy ("retrieved dropouts") imputation approach”
> “Missing data due to death was multiply imputed by using 5% worst outcome.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-4"></a>

##### Analysis of the obesity and within-participant secondary hypotheses

> “The test is for the difference in slopes between the lorundrostat and placebo.”
> “A paired t-test comparing the value at baseline and value at Week 12.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-5"></a>

##### Sensitivity analyses of the primary endpoint

> “Values for all participants with intercurrent events after the occurrence of intercurrent event were treated as missing at random.”
> “Values for all participants with missing data regardless of cause were treated as Missing Not at Random (MNAR) and were assumed to trend with placebo distribution.”
> “No imputation was performed; the analysis used observed data only.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.7.2-6"></a>

##### Population of the responder analysis

> “In this secondary analysis, we included participants in the 50 mg lorundrostat or placebo groups with AOSBP ≥130 mmHg at baseline. Adjusted odds ratio of achieving SBP <130 mmHg at week 12 was analyzed in multiply imputed datasets using a treatment policy approach.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.7.2-7"></a>

##### Definition of chronic kidney disease in the subgroup analysis

> “CKD was defined as eGFR <60mL/min/1.73m2 or UACR ≥30mg/g.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

> “Post hoc analysis from pivotal Launch-HTN trial shows statistically significant and clinically meaningful reductions in blood pressure in participants with chronic kidney disease”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8"></a>

### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

#### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

##### Screening, run-in, randomization, and dosing

> “Between November 24, 2023, and September 16, 2024, 3161 participants were screened, 1575 entered the placebo-run in phase, and 1083 were randomized to the double-blind treatment phase”
> “Of the 1083 participants randomized, 1078 received at least 1 dose of 50 mg/d of lorundrostat for 6 weeks with the potential dose increase to 100 mg/d (n = 270), 50 mg/d of lorundrostat for 12 weeks (n = 538), or daily placebo for 12 weeks (n = 270) (Figure 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-2"></a>

##### Most frequent reasons for exclusion

> “The most frequent reasons were current use of treatment (or anticipated treatment) with any of the prohibited medications described in the trial protocol within a specified time frame (n = 15); had a condition that would preclude participation in the study (based on the opinion of the investigator) (n = 14); and had current, known, or presumed orthostatic hypotension (n = 9).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-3"></a>

##### Escalation to 100 mg at week 6

> “Of the 270 participants randomized to 50 mg of lorundrostat once daily, 92 (34.1%) were escalated to the 100-mg dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.1-4"></a>

##### Intercurrent events and missing data

> “Altogether, there were 24 intercurrent events (ICE), 23 due to treatment discontinuation for AEs and one for death. Of these, 10/1078 (0.9%) were missing data at Week 6 for AE, and 13 were not missing Week 6 data. At Week 12, 12/1078 (1.1%) were missing data for AE, 1/1078 (0.1%) due to death and 12 completed the trial ("retrieved dropouts").”
> “Remaining missing data (56/1078, 5.2%) at Week 6 and (67/1078, 6.2%) at Week 12 were considered missing at random (MAR) and were multiply imputed following the distribution in the group to which they were randomized.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.1-5"></a>

##### Enrollment of lorundrostat-treated participants in the open-label extension

> “Of the 808 participants from Launch-HTN's lorundrostat treatment arms, 632 participants were eligible and enrolled in Transform-HTN.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="heading-3.1.1.8.2"></a>

#### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

##### Demographic summary of the randomized population

> “Of the 1083 participants, the mean age was 61.6 years (SD, 10.3 years), 508 (46.9%) were female, 311 (28.7%) were Black or African American, 733 (67.7%) were White, and 685 (63.3%) had a body mass index of 30 or greater (obesity). At randomization, 432 participants (39.9%) were taking 2 prescribed antihypertensive medications and 651 (60.1%) were taking 3 or more.”
> “The randomized groups were comparable for the baseline demographic and clinical characteristics (Table 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.2-2"></a>

##### Baseline characteristics by randomized group

| Characteristic | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 541) | Placebo (n = 272) |
| --- | --- | --- | --- |
| Age, mean (SD), y | “61.4 (10.3)” | “61.7 (10.6)” | “61.8 (10.4)” |
| Male, No. (%) | “142 (52.6)” | “294 (54.3)” | “139 (51.1)” |
| Female, No. (%) | “128 (47.4)” | “247 (45.7)” | “133 (48.9)” |
| Asian, No. (%) (lorundrostat n = 267 and n = 535) | “4 (1.5)” | “14 (2.6)” | “6 (2.2)” |
| Black or African American, No. (%) (lorundrostat n = 267 and n = 535) | “72 (26.7)” | “152 (28.1)” | “87 (32.0)” |
| White, No. (%) (lorundrostat n = 267 and n = 535) | “190 (70.4)” | “366 (67.7)” | “177 (65.1)” |
| Hispanic or Latino ethnicity, No. (%) | “102 (37.8)” | “191 (35.3)” | “101 (37.1)” |
| Body mass index, mean (SD) | “32.8 (6.7)” | “33.0 (6.9)” | “32.6 (7.4)” |
| Body mass index ≥30 (obesity), No. (%) | “166 (61.5)” | “351 (64.9)” | “168 (61.8)” |
| eGFR at randomization, mean (SD), mL/min/1.73 m2 | “92.8 (17.6)” | “90.1 (17.8)” | “91.2 (16.4)” |
| eGFR ≥60 mL/min/1.73 m2, No. (%) | “255 (94.4)” | “500 (92.9)” | “260 (96.3)” |
| Diabetes, No. (%) | “76 (28.2)” | “173 (32.2)” | “89 (33.0)” |
| Taking 2 antihypertensive medications, No. (%) | “106 (39.3)” | “213 (39.4)” | “113 (41.5)” |
| Taking ≥3 antihypertensive medications, No. (%) | “164 (60.7)” | “328 (60.6)” | “159 (58.5)” |
| Thiazide or thiazide-like diuretic, No. (%) | “259 (95.9)” | “520 (96.1)” | “259 (95.2)” |
| ACE inhibitor or ARB, No. (%) | “237 (87.8)” | “467 (86.3)” | “225 (82.7)” |
| Calcium channel blocker, No. (%) | “140 (51.9)” | “278 (51.4)” | “135 (49.6)” |
| Glucagon-like peptide-1 receptor agonists, No. (%) | “13 (4.8)” | “30 (5.6)” | “9 (3.3)” |
| Sodium-glucose cotransporter 2 inhibitors, No. (%) | “14 (5.2)” | “21 (3.9)” | “13 (4.8)” |
| Systolic blood pressure, mean (SD), mm Hg | “146.6 (11.1)” | “149.0 (12.2)” | “148.8 (12.2)” |
| Systolic blood pressure <140 mm Hg, No. (%) | “83 (30.7)” | “137 (25.3)” | “73 (26.8)” |
| Systolic blood pressure 140 to <160 mm Hg, No. (%) | “152 (56.3)” | “294 (54.3)” | “144 (52.9)” |
| Systolic blood pressure ≥160 mm Hg, No. (%) | “35 (13.0)” | “110 (20.3)” | “55 (20.2)” |
| Diastolic blood pressure, mean (SD), mm Hg | “86.3 (9.2)” | “87.8 (9.0)” | “87.1 (9.1)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.2-3"></a>

##### Baseline characteristics of the responder analysis population

> “(mean age, 61.9 years; 47.1% female; 29.6% Black; 63.8% BMI ≥30 kg/m2; mean SBP, 149.4 mmHg; 60.1% using ≥3 AHTs)”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.8.2-4"></a>

##### Baseline characteristics of participants with chronic kidney disease

> “Among participants with CKD (n=192), 71% were receiving three or more anti-hypertensive medications at baseline, compared with 56% of those without CKD. In addition, 31% of participants with CKD had systolic blood pressure (SBP) ≥160 mmHg at baseline, versus 17% of participants without CKD.”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8.3"></a>

#### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

##### Primary endpoint: change in office systolic blood pressure at week 6

> “The least-squares mean change in office systolic BP at week 6 was −16.9 mm Hg (95% CI, −19.0 to −14.9 mm Hg) for the pooled 50 mg of lorundrostat group vs −7.9 mm Hg (95% CI, −11.5 to −4.2 mm Hg) for the placebo group (least-squares between-group mean difference, −9.1 mm Hg [95% CI, −13.3 to −4.9 mm Hg], P < .001; Table 2 and Figure 2).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-2"></a>

##### Primary, secondary, and prespecified exploratory blood pressure outcomes

| Outcome | Lorundrostat baseline, mean (SD) | Lorundrostat follow-up, mean (SD) | Lorundrostat least-squares mean change (95% CI) | Placebo baseline, mean (SD) | Placebo follow-up, mean (SD) | Placebo least-squares mean change (95% CI) | Least-squares mean difference (95% CI) | P value |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Primary: systolic BP, baseline to 6 wk (pooled lorundrostat n = 808; placebo n = 270) | “148.2 (11.9)” | “133.6 (15.3)” | “−16.9 (−19.0 to −14.9)” | “148.6 (12.1)” | “140.7 (15.0)” | “−7.9 (−11.5 to −4.2)” | “−9.1 (−13.3 to −4.9)” | “<.001” |
| Secondary: systolic BP <130 mm Hg at 6 wk, No. (%); difference as odds ratio (95% CI) | “20 (2.5)” | “356 (44.1)” | “NA” | “NA” | “65 (24.1)” | “NA” | “3.4 (1.5 to 7.8)” | “.003” |
| Secondary: taking 2 antihypertensive drugs, 6 wk (lorundrostat n = 318; placebo n = 112; 97.5% CI where reported) | “147.6 (11.5)” | “134.2 (14.9)” | “−16.1 (−19.1 to −13.0)” | “148.0 (11.3)” | “141.4 (14.4)” | “−7.2 (−11.7 to −2.8)” | “−8.8 (−14.8 to −2.9)” | “<.001” |
| Secondary: taking ≥3 antihypertensive drugs, 6 wk (lorundrostat n = 490; placebo n = 158; 97.5% CI) | “148.6 (12.1)” | “133.2 (15.6)” | “−17.2 (−19.6 to −14.7)” | “149.0 (12.6)” | “140.4 (15.5)” | “−8.1 (−12.4 to −3.8)” | “−9.0 (−14.0 to −4.1)” | “<.001” |
| Secondary: systolic BP, baseline to 12 wk, escalated dose group (lorundrostat n = 270) | “146.6 (11.1)” | “131.9 (14.3)” | “−15.7 (−19.3 to −12.2)” | “148.6 (12.1)” | “141.2 (15.4)” | “−7.3 (−11.1 to −3.5)” | “−8.4 (−13.6 to −3.2)” | “.002” |
| Secondary: within-participant analysis, 12 wk (n = 92; 97.5% CI) | “148.3 (12.4)” | “138.1 (14.8)” | “−10.2 (−14.3 to −6.1)” | “NA” | “NA” | “NA” | “NA” | “<.001” |
| Exploratory: diastolic BP, baseline to 6 wk | “87.3 (9.1)” | “79.9 (10.4)” | “−8.6 (−9.9 to −7.3)” | “87.1 (9.0)” | “83.2 (10.1)” | “−5.2 (−7.4 to −3.0)” | “−3.4 (−5.9 to −0.8)” | “.01” |
| Exploratory: systolic BP, baseline to 12 wk, 50 mg group (lorundrostat n = 538) | “149.1 (12.2)” | “132.5 (16.0)” | “−19.0 (−21.6 to −16.3)” | “148.6 (12.1)” | “141.2 (15.4)” | “−7.3 (−11.1 to −3.5)” | “−11.6 (−16.3 to −7.0)” | “<.001” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-3"></a>

##### Observed proportion with office systolic blood pressure below 130 mm Hg at week 6

> “The estimated proportions are based on multiple imputed data. The observed data were 332/755 (44.0%) for lorundrostat vs 62/257 (24.1%) for placebo.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-4"></a>

##### Key secondary endpoints at week 6

> “An office systolic BP of less than 130 mm Hg at week 6 was achieved by 44.1% of participants in the pooled 50 mg of lorundrostat group vs 24.1% of participants in the placebo group (odds ratio, 3.4 [95% CI, 1.5 to 7.8]; P = .003).”
> “Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −8.8 mm Hg (97.5% CI, −14.8 to −2.9 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 2 prescribed antihypertensive medications. Compared with placebo, the least-squares mean change in office systolic BP at week 6 was −9.0 mm Hg (97.5% CI, −14.0 to −4.1 mm Hg; P < .001) for participants in the pooled 50 mg of lorundrostat group taking 3 or more antihypertensive medications.”
> “A comparable reduction in office systolic BP was observed across the continuum of BMI represented in the trial; 91.6% of participants had a BMI of 25 or greater.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-5"></a>

##### Key secondary endpoints at week 12 with escalation to 100 mg

> “Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −8.4 mm Hg (95% CI, −13.6 to −3.2 mm Hg; P = .002) for participants randomized to 50 mg of lorundrostat for 6 weeks and then possibly 100 mg for 6 weeks. Compared with placebo, the least-squares mean change in office systolic BP at week 12 was −10.2 mm Hg (97.5% CI, −14.3 to −6.1 mm Hg; P < .001) for the 92 participants who escalated from 50 mg of lorundrostat to 100 mg.”
> “Increasing the 50-mg/d dose of lorundrostat to 100 mg/d provided no additional benefit to participants who did not reach the goal BP using the 50-mg/d dose.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-6"></a>

##### Subgroup consistency of the primary endpoint

> “The efficacy of lorundrostat for lowering BP was consistent across age, sex, race, BMI, and number of prescribed antihypertensive medications participants were taking (Figure 3).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.3-7"></a>

##### Prespecified exploratory endpoints: diastolic blood pressure at week 6 and systolic blood pressure at week 12

> “Placebo-adjusted least squared mean change in AODBP at Week 6 was -3.4 mmHg (95% CI, - 5.9 to -0.8, p=0.01).”
> “The AOSBP reduction observed with lorundrostat 50 mg at Week 6 was maintained at Week 12 with LSM (SE) change in AOSBP of -19.0 (1.4) mmHg for lorundrostat 50mg and -7.3 (1.95) mmHg for placebo (placebo-adjusted LSM change of -11.6 mmHg; 95% CI, -16.3 to -7.0, p<0.001).”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-8"></a>

##### Sensitivity analyses of the primary endpoint

| Analysis | Lorundrostat LS mean (SE) | Placebo LS mean (SE) | LS mean difference (SE) | 95% CI of LS mean difference | P value |
| --- | --- | --- | --- | --- | --- |
| Sensitivity analysis 1: intercurrent events treated as missing at random (lorundrostat n = 808; placebo n = 270) | “-16.9 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |
| Sensitivity analysis 2: all missing data treated as missing not at random (lorundrostat n = 808; placebo n = 270) | “-16.5 (1.1)” | “-7.9 (1.9)” | “-8.6 (2.2)” | “-12.2 to -4.4” | “<0.001” |
| Sensitivity analysis 4: observed data only (lorundrostat n = 755; placebo n = 257) | “-17.0 (1.1)” | “-7.9 (1.9)” | “-9.1 (2.1)” | “-13.3 to -4.9” | “<0.001” |

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-9"></a>

##### Tipping point sensitivity analysis

> “There was no tipping point within maximum prespecified increment of +40 mmHg/-40 mmHg”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.3-10"></a>

##### Week 6 and week 12 results in the topline announcement, March 2025

> “Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at week 6”
> “Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value < 0.0001) assessed by automated office blood pressure at end of treatment, week 12”
> “The change in blood pressure in response to lorundrostat in subjects using two background antihypertensives (uncontrolled) or three to five (resistant) were similar, and both were statistically significantly different from the response in those taking placebo.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.1.8.3-11"></a>

##### Week 12 placebo-adjusted result in the annual report

> “The Launch-HTN global Phase 3 trial demonstrated a statistically significant and clinically meaningful 11.6 mmHg placebo-adjusted”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-3.1.1.8.3-12"></a>

##### Responder analysis: office systolic blood pressure below 130 mm Hg and reductions of 5, 10, and 20 mm Hg at week 12

> “The guideline-recommended target of AOSBP <130 mmHg at week 12 was achieved by 46.3% and 19.9% of participants in the lorundrostat and placebo groups, respectively (odds ratio, 3.86; 95% CI, 2.66-5.60; P<0.0001;”
> “At week 12, 79%, 70%, and 41% of participants treated with lorundrostat had an SBP reduction of ≥5 mmHg, ≥10 mmHg, and ≥20 mmHg, respectively.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

> “showing that at Week 12, 46% of lorundrostat-treated participants achieved the AHA/ACC Guideline recommended office systolic blood pressure (SBP) target of <130 mmHg.”

Source: [Mineralys Therapeutics press release, AHA Hypertension 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/121/mineralys-therapeutics-presents-new-data-for-lorundrostat)

<a id="topic-3.1.1.8.3-13"></a>

##### Participants with and without chronic kidney disease: systolic blood pressure and albuminuria at week 12

> “Placebo-adjusted reduction in AOSBP was -12.2 mmHg and -9.6 mmHg in participants without and with CKD, respectively (Table). Placebo-adjusted percent change in geometric mean UACR in LOR 50mg participants with baseline albuminuria at week 12 was -52.2% (95% CI, -64.0 to -36.6; P<0.001).”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-3.1.1.8.3-14"></a>

##### Participants with and without chronic kidney disease: results by stage

| CKD stage (placebo N; lorundrostat 50 mg N) | Placebo AOSBP LSM (95% CI) change at week 12 | Lorundrostat 50 mg AOSBP LSM (95% CI) change at week 12 | Placebo adjusted (95% CI) | Placebo week 12 % with AOSBP <130 mmHg | Lorundrostat 50 mg week 12 % with AOSBP <130 mmHg |
| --- | --- | --- | --- | --- | --- |
| No CKD (202; 406) | “-7.2 (-11.3, -3.2)” | “-19.4 (-22.2, -16.6)” | “-12.2 (-17.1, -7.3)” | “22.1” | “48.0” |
| Stage 1 (30; 58) | “-8.9 (-15.4, -2.3)” | “-19.5 (-24.1, -14.9)” | “-10.6 (-18.6, -2.6)” | “18.4” | “50.6” |
| Stage 2 (25; 31) | “-9.1 (-15.9, -2.4)” | “-16.7 (-22.6, -10.8)” | “-7.6 (-16.5, 1.4)” | “12.0” | “28.4” |
| Stage 3 (10; 38) | “-8.5 (-18.1, 1.1)” | “-18.5 (-24.1, -13.0)” | “-10.1 (-21.1, 1.0)” | “30.0” | “47.0” |

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="topic-3.1.1.8.3-15"></a>

##### Participants with chronic kidney disease: P values and albuminuria population

> “At week 12, placebo-adjusted SBP reductions were 9.6 mmHg in participants with CKD (p=0.0022) and 12.2 mmHg in those without CKD (p<0.0001). A greater proportion of lorundrostat-treated participants also achieved target SBP of <130 mmHg at week 12 compared with placebo, both among CKD participants (44% vs 18%) and non-CKD participants (48% vs 22%).”
> “Lorundrostat treatment was also associated with a significant placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among 84 participants with CKD and baseline albuminuria, achieving a 52.2% placebo-adjusted reduction at 12 weeks (p<0.0001).”

Source: [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="heading-3.1.1.8.4"></a>

#### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

#### 3.1.1.8.5 Safety Results

<a id="topic-3.1.1.8.5-1"></a>

##### Adverse events by randomized group

| Event, No. (%) | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 538) | Placebo (n = 270) |
| --- | --- | --- | --- |
| Died | “0” | “0” | “1 (0.4)” |
| Serious adverse event | “2 (0.7)” | “12 (2.2)” | “8 (3.0)” |
| Treatment-emergent adverse event, severe | “6 (2.2)” | “9 (1.7)” | “8 (3.0)” |
| Treatment-emergent adverse event, moderate | “30 (11.1)” | “100 (18.6)” | “31 (11.5)” |
| Treatment-emergent adverse event, mild | “115 (42.6)” | “180 (33.5)” | “59 (21.9)” |
| Special interest: severely elevated blood pressure | “2 (0.7)” | “10 (1.9)” | “11 (4.1)” |
| Special interest: hypotension with symptoms | “5 (1.9)” | “11 (2.0)” | “1 (0.4)” |
| Special interest: hyperkalemia | “7 (2.6)” | “11 (2.0)” | “1 (0.4)” |
| Special interest: hyponatremia | “28 (10.4)” | “37 (6.9)” | “9 (3.3)” |
| Special interest: glucocorticoid deficiency | “0” | “0” | “3 (1.1)” |
| Special interest: reduction in estimated glomerular filtration rate | “9 (3.3)” | “16 (3.0)” | “2 (0.7)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-2"></a>

##### Overall adverse events, serious adverse events, and deaths

> “Treatment-emergent adverse events were experienced by 49.9% of participants (538/1078) and were mostly mild or moderate in severity (Table 3). Serious adverse events occurred in 22 participants and included 1 event that was considered to be related to treatment. One participant in the placebo group died after week 6 (unrelated to treatment).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-3"></a>

##### Definitions used in the adverse event table

> “Defined as systolic blood pressure greater than 180 mm Hg or diastolic blood pressure greater than 110 mm Hg.”
> “Trial drug had to be modified due to the adverse event (dose reduction, interruption, or discontinuation).”
> “Confirmed by adrenocorticotropic hormone (cosyntropin or regional equivalent) stimulation test; trial drug was discontinued.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-4"></a>

##### Serum potassium above 6.0 mmol/L

> “A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo (eTable 4 in Supplement 1). The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range (eFigure 5 in Supplement 1).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-5"></a>

##### Serum sodium and potassium thresholds by randomized group

| Level, n (%) | Lorundrostat 50 to 100 mg daily (n=270) | Lorundrostat 50 mg (n=538) | Placebo (n=270) |
| --- | --- | --- | --- |
| Serum sodium <132 mmol/L | “22 (8.1)” | “38 (7.1)” | “13 (4.8)” |
| Serum sodium <130 mmol/L | “11 (4.1)” | “14 (2.6)” | “4 (1.5)” |
| Serum sodium <125 mmol/L | “4 (1.5)” | “4 (0.7)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, single value | “29 (10.7)” | “38 (7.1)” | “3 (1.1)” |
| Serum potassium 6.1 to 6.5 mmol/L, single value | “2 (0.7)” | “5 (0.9)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, single value | “2 (0.7)” | “1 (0.2)” | “1 (0.4)” |
| Serum potassium 5.6 to 6.0 mmol/L, confirmed | “24 (8.9)” | “31 (5.8)” | “2 (0.7)” |
| Serum potassium 6.1 to 6.5 mmol/L, confirmed | “2 (0.7)” | “3 (0.6)” | “1 (0.4)” |
| Serum potassium >6.5 mmol/L, confirmed | “1 (0.4)” | “0” | “0” |

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.5-6"></a>

##### Counting rules for the sodium and potassium table

> “Number of participants with at least one clinical laboratory report meeting the corresponding level at any laboratory during the double-blind treatment period. A participant is included only in the highest level observed.”
> “These confirmatory measurements were performed to account for cases of factitious hyperkalemia such as hemolyzed samples. Participants were counted if repeat value obtained on study drug confirmed potassium level ≥5.6 mmol/L.”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

<a id="topic-3.1.1.8.5-7"></a>

##### Confirmed hyperkalemia reported by the company

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 1.1% and 1.5% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 0.6% and 1.1% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “A confirmed serum potassium level of greater than 6.0 mmol/L occurred in three subjects (0.6%) on lorundrostat 50 mg once daily, as compared to one subject (0.4%) on placebo.”

Source: [Mineralys Therapeutics press release, Launch-HTN JAMA publication (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/74/mineralys-therapeutics-announces-journal-of-the-american)

<a id="topic-3.1.1.8.5-8"></a>

##### Kidney function: creatinine-based and cystatin C-based eGFR

> “Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.”
> “The observed decline in eGFR (assessed using the cystatin C–based eGFR formula to correct for falsely elevated creatinine due to competition between lorundrostat and creatinine for MATE [multidrug and toxin extrusion] 1–dependent transport) after initiation of lorundrostat was expected.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-9"></a>

##### Cortisol and glucocorticoid insufficiency

> “At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.”
> “The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group. No participants treated with lorundrostat experienced a glucocorticoid deficiency (confirmed by stimulation testing; Table 3). There were no reports of hyperadrenocorticism.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-10"></a>

##### Treatment discontinuation due to hyperkalemia, hyponatremia, or reduced kidney function

> “Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR). Among participants in the placebo group, there were no treatment discontinuations due to hyperkalemia, hyponatremia, or reduction in kidney function.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.8.5-11"></a>

##### Serious adverse events reported in the topline announcement

> “In the Launch-HTN trial there were 12 subjects (2.2%) and two subjects (0.7%) with treatment-emergent serious adverse events (SAEs) in the 50 mg and 50 mg with optional dose escalation to 100 mg arms, respectively, compared with eight subjects (3.0%) in the placebo arm. There was only one subject (0.1%) in the trial with treatment-related SAEs that occurred in the 50 mg arm.”

Source: [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.1.8.5-12"></a>

##### Confirmed hyperkalemia and symptomatic hypotension in the responder analysis

> “In the lorundrostat 50 mg and placebo groups, 3 (0.6%) and 1 (0.4%) participants had confirmed serum potassium >6.0 mmol/L, respectively. Symptomatic hypotension was reported in 11 (2.0%) participants in the lorundrostat 50 mg group and 1 (0.4%) in the placebo group.”

Source: [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461)

<a id="topic-3.1.1.8.5-13"></a>

##### Participants with chronic kidney disease: potassium and cystatin C-based eGFR

> “Among participants receiving LOR 50mg, confirmed serum potassium >6.0 mmol/L occurred in 3 (2.4%) CKD participants and in none of the non-CKD participants. In LOR 50mg participants, mean cystatin C-based eGFR decreased by 7.3, 4.0 and 4.2 mL/min/1.73 m2 in those with CKD stage 1, 2, and 3, respectively, compared with 2.1 mL/min/1.73 m2 in those without CKD.”

Source: [Vogt et al. (2026)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.2026fy6zb248~blood-pressure-and-albuminuria-reduction-with-lorundrostat)

<a id="heading-3.1.1.9"></a>

### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

#### Summary: study limitations

Launch-HTN randomized 1,083 participants and compared lorundrostat with placebo for 12 weeks, a duration the investigators describe as “consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration”. Longer-term data come from the open-label extension, which enrolled 632 of the 808 participants who received lorundrostat in Launch-HTN. The trial had no active comparator. The primary endpoint, unattended automated office systolic blood pressure at week 6, was chosen “to reflect usual clinical practice”; the investigators note that ambulatory measurement “is the gold standard for assessment of BP”. FDA guidance attributes the cardiovascular benefits of antihypertensive drugs largely to the decrease in blood pressure, and the trial did not measure cardiovascular outcomes.

In the escalation group, 92 of 270 participants (34.1%) met the week 6 criteria and received 100 mg, and the investigators conclude that the higher dose “provided no additional benefit” to participants who had not reached goal on 50 mg; the week 12 placebo-adjusted difference in the escalation group (−8.4 mm Hg) was smaller than in the 50 mg group (−11.6 mm Hg). Two week 12 values are reported for the 50 mg group: −11.6 mm Hg in the publication and 11.7 mm Hg in the March 2025 topline announcement.

Eligibility excluded people with eGFR below 45 mL/min/1.73 m2, serum potassium above 5.0 mmol/L at screening or above 4.8 mmol/L at randomization, serum sodium below 135 mmol/L, or heart failure, myocardial infarction, stroke, or transient ischemic attack within 6 months, and prohibited mineralocorticoid receptor antagonists, epithelial sodium channel inhibitors, and potassium-sparing diuretics. Of the 1,083 participants, 685 (63.3%) had obesity and 432 (39.9%) were taking 2 antihypertensive medications, so the population includes people who would not meet the 2025 AHA/ACC definition of resistant hypertension. Three participants were randomized in Canada. The publication reports 159 sites in 13 countries, while the registry lists 184 locations. Hyperkalemia rates depend on the definition: a single serum potassium above 6.0 mmol/L occurred in 1.5% and 1.1% of the two lorundrostat groups and 0.7% of the placebo group, while the company reports confirmed hyperkalemia of 1.1% and 0.6%, respectively. The responder analysis is described as a “secondary analysis” and the chronic kidney disease analysis as a “Post hoc analysis”; both are published as conference abstracts. No health-related quality of life or patient-reported outcome was reported. The sponsor's chief medical officer and lead statistician are listed among the sponsor leadership of the trial and are authors of the publication.

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/); [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf); [ClinicalTrials.gov NCT06153693](https://clinicaltrials.gov/study/NCT06153693); [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from); [Mineralys Therapeutics press release, Launch-HTN and Advance-HTN topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/60/mineralys-therapeutics-announces-positive-topline-results); [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm); [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download); [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356); [Saxena et al. (2026a)](https://www.ahajournals.org/doi/10.1161/hyp.83.suppl_1.FR461); [Mineralys Therapeutics press release, ESH 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/103/mineralys-therapeutics-presents-new-data-from-the-phase-3)

<a id="topic-3.1.1.9-2"></a>

#### Limitations stated by the investigators

> “This trial has limitations. First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.”
> “Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice. Importantly, the phase 2 Advance-HTN trial18 of lorundrostat used 24-hour ambulatory BP measurements and, compared with placebo, demonstrated similar patterns of BP lowering after 12 weeks of treatment.”
> “Third, the current trial compared the efficacy of lorundrostat vs placebo, but the trial did not include an active comparator.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-3.1.1.9-3"></a>

#### Out-of-office measurement and cardiovascular risk prediction

> “both home BP and 24-hour ABPM are shown to be superior to office BP in predicting cardiovascular events.”

Source: [Jones et al. (2025)](https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356)

<a id="topic-3.1.1.9-4"></a>

#### Sponsor leadership of the trial

> “Mineralys Therapeutics, Inc (Sponsor Leadership): David Rodman, MD (Chief Medical Officer); Branko Kopjar MD (Lead Statistician); Jessica Ibbitson (Senior Vice President, Clinical Operations)”

Source: [Saxena et al. supplementary appendix (2025)](https://pmc.ncbi.nlm.nih.gov/articles/instance/12210145/bin/jama-e259413-s001.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
